T he Centers for Disease Control used to have a vaccine advisory panel made of well-respected experts. This panel, the ...

The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The FDA halted enrollment of young children in RSV vaccine trials after five infants in one study developed severe RSV infections. An FDA panel asked for additional data to better understand what ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

In July 2023, Moderna (MRNA) started an FDA process for real-time review of mRNA-1345 backed by late-stage data, which indicated a vaccine efficacy of 83.7% as defined by two or more RSV symptoms ...

The Food and Drug Administration (FDA) has approved Moderna’s RSV mRNA vaccine for adults older than 60 years. The approval makes RSV the second disease for which an mRNA vaccine has been ...

Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. The company had previously said its vaccine could be used ...

Abrysvo stimulates the mother's immune system to produce antibodies that cross the placenta and offer protection to the newborn against RSV illness, starting at birth. The FDA based its approval ...

Abrysvo stimulates the mother’s immune system to produce antibodies that cross the placenta and offer protection to the newborn against RSV illness, starting at birth. The FDA based its approval ...